What is the upside for Solaris resources'stock?
Their forecasts range from $16.00 to $21.00. On average, they expect Solaris Resources' share price to reach $18.67 in the next twelve months. This suggests a possible upside of 61.5% from the stock's current price.
What are analysts'target prices for Solaris resources'stock?
4 Wall Street analysts have issued twelve-month target prices for Solaris Resources' stock. Their forecasts range from $16. 00 to $21. 00. On average, they expect Solaris Resources' share price to reach $18. 67 in the next twelve months. This suggests a possible upside of 61. 5% from the stock's current price.
What is the stock price of Solaris oilfield infrastructure?
Since then, SOI shares have increased by 20.4% and is now trading at $7.38. View which stocks have been most impacted by COVID-19. Are investors shorting Solaris Oilfield Infrastructure? Solaris Oilfield Infrastructure saw a increase in short interest in December.
Should you buy Solaris resources (Sri) stock?
4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Solaris Resources in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Solaris Resources stock.
Is SLRX a good stock to buy?
Salarius Pharmaceuticals Inc (NASDAQ:SLRX) The 1 analysts offering 12-month price forecasts for Salarius Pharmaceuticals Inc have a median target of 5.00, with a high estimate of 5.00 and a low estimate of 5.00. The median estimate represents a +2,327.18% increase from the last price of 0.21.
What happened to Salarius pharmaceuticals?
(Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that Salarius Pharmaceuticals, LLC, has closed its merger with Flex Pharma, Inc.'s wholly owned subsidiary on July 19, 2019. Flex Pharma, Inc. has been renamed and will operate as Salarius Pharmaceuticals, Inc.
Is SOI stock a buy right now?
2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Solaris Oilfield Infrastructure in the last year. There...
Will Solaris Oilfield Infrastructure's stock price go up in 2022?
2 analysts have issued twelve-month price objectives for Solaris Oilfield Infrastructure's stock. Their forecasts range from $10.00 to $12.00. On a...
How has Solaris Oilfield Infrastructure's stock performed in 2022?
Solaris Oilfield Infrastructure's stock was trading at $6.55 at the beginning of 2022. Since then, SOI stock has increased by 103.4% and is now tra...
When is Solaris Oilfield Infrastructure's next earnings date?
Solaris Oilfield Infrastructure is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022. View our earnings f...
How were Solaris Oilfield Infrastructure's earnings last quarter?
Solaris Oilfield Infrastructure, Inc. (NYSE:SOI) released its quarterly earnings data on Thursday, April, 28th. The company reported $0.11 EPS for...
How often does Solaris Oilfield Infrastructure pay dividends? What is the dividend yield for Solaris Oilfield Infrastructure?
Solaris Oilfield Infrastructure declared a quarterly dividend on Thursday, May 12th. Investors of record on Tuesday, June 7th will be paid a divide...
Is Solaris Oilfield Infrastructure a good dividend stock?
Solaris Oilfield Infrastructure(NYSE:SOI) pays an annual dividend of $0.42 per share and currently has a dividend yield of 2.96%. The dividend payo...
Who are Solaris Oilfield Infrastructure's key executives?
Solaris Oilfield Infrastructure's management team includes the following people: Mr. William A. Zartler , Founder, Chairman & CEO (Age 57, Pay $...
Who are some of Solaris Oilfield Infrastructure's key competitors?
Some companies that are related to Solaris Oilfield Infrastructure include NOW (DNOW) , Dril-Quip (DRQ) , Oil States International (OIS) , Newp...
Should I buy or sell Solaris Resources stock right now?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Solaris Resources in the last year. There are currently 5 buy ratings for...
What is Solaris Resources' stock price forecast for 2022?
5 analysts have issued 12 month price targets for Solaris Resources' shares. Their forecasts range from $19.00 to $25.00. On average, they expect S...
How has Solaris Resources' stock price performed in 2022?
Solaris Resources' stock was trading at $13.41 at the beginning of the year. Since then, SLSSF stock has decreased by 35.1% and is now trading at $...
Are investors shorting Solaris Resources?
Solaris Resources saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 650,700 shares, an in...
When is Solaris Resources' next earnings date?
Solaris Resources is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022. View our earnings forecast for Sol...
Who are Solaris Resources' key executives?
Solaris Resources' management team includes the following people: Mr. Richard William Warke , Exec. Chairman (Age 62, Pay $164.94k) Mr. Daniel E...
Who are some of Solaris Resources' key competitors?
Some companies that are related to Solaris Resources include 29Metals (29M) , Aya Gold & Silver (AYASF) , Aya Gold & Silver (MYAGF) , Ballymore...
What is Solaris Resources' stock symbol?
Solaris Resources trades on the OTCMKTS under the ticker symbol "SLSSF."
How do I buy shares of Solaris Resources?
Shares of SLSSF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBu...
What is Solaris Pharma?
Solaris Pharma Corporation is a leading specialty dermatology company committed to the identifying, developing and marketing of high-quality, generic and specialty pharmaceutical products.
Why are dermatology products so challenging?
Dermatology products are challenging to develop and manufacture with complexities arising from formulation & process development, stability and scale up . In addition, a majority of the dermatology products require expensive clinical studies, which act as a barrier to entry for a lot of companies.
About Solaris Oilfield Infrastructure
Solaris Oilfield Infrastructure, Inc. operates as a holding company, which engages in the manufacture of patented mobile proppant management systems that unload, store, and deliver proppant at oil and natural gas well sites. Its products include Mobile Proppant and Mobile Chemical Management Systems, and Inventory Management Software.
Headlines
Solaris Oilfield Infrastructure Inc (SOI) CHAIRMAN AND CEO William A Zartler Bought $66,400 of ...
Solaris Oilfield Infrastructure (NYSE:SOI) Frequently Asked Questions
2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Solaris Oilfield Infrastructure in the last year. There are currently 1 hold rating and 1 buy rating for the stock.
About Solaris Resources
Solaris Resources Inc., engages in acquisition, exploration, and development of mineral properties. It focuses on exploring copper, molybdenum, gold, lead, zinc, and silver. The company primarily holds interest in Warintza property covering an area of 26,777 hectares located in southeastern Ecuador.
Headlines
Is Solaris Resources (TSE:SLS) In A Good Position To Invest In Growth?
Solaris Resources (OTCMKTS:SLSSF) Frequently Asked Questions
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Solaris Resources in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Solaris Resources stock. View analyst ratings for Solaris Resources or view top-rated stocks.
NASDAQ: MRNA
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Good news! There's a way to avoid this portfolio pain -- and it doesn't involve avoiding the whole sector
If you've ever felt like biotech stocks seem to start collapsing just as soon as you buy them, you're not alone: Many investors have had the unpleasant experience of discovering a hot biotech company as it was trending upward and buying some shares, only to see its price take a significant dive more or less immediately afterward.
You're buying the news instead of selling it
If you find that biotech stocks tend to go down right after you buy them, the central reason is likely that you're investing right after these companies experience major catalysts.
NASDAQ: MRNA
Let's use Annovis Bio ( ANVS -1.14% ) as an example. On May 21, it reported that in a phase 2 clinical trial, its Alzheimer's disease drug candidate appeared to improve the cognitive functioning of patients. That news caused the stock to pop by nearly 150%, adding to a great run for the year.
Diversify your holdings to reduce the impact of the unpredictable
If you decide to buy Moderna stock before Sept. 9, what happens if management reports that the project you're interested in hasn't lived up to their hopes? The stock will drop, of course -- which will sting. But without taking that risk, it's much harder to gain from the alternate scenario in which the company reports a success.
Premium Investing Services
Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.